• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Diabetes Market to 2016 - Biguanides and Insulin Analogs will be the Largest Selling Anti-Diabetic Drugs - Product Image

Diabetes Market to 2016 - Biguanides and Insulin Analogs will be the Largest Selling Anti-Diabetic Drugs

  • Published: December 2010
  • 153 Pages
  • GBI Research

FEATURED COMPANIES

  • Amylin Pharmaceuticals
  • Eli Lilly
  • GlaxoSmithKline (GSK)
  • Merck & Co Inc
  • Novo Nordisk
  • Sanofi-Aventis
  • MORE

“Diabetes Market to 2016 - Biguanides and Insulin Analogs to be the Largest Selling Anti-Diabetic Drugs” provides in-depth analysis of unmet needs, drivers and barriers that impact the global diabetes therapeutics market.. Treatment usage patterns, sales, prices and volumes are forecast until 2016 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

Scope

The scope of this report includes:
- Annualized market data for the diabetes therapeutics market from 2001 to 2009, forecast forward to 2016.
- Market characterization of the diabetes therapeutics market, including market size, annual cost of therapy and treatment usage patterns.
- Key drivers and barriers that have a significant impact on the market.
- Coverage of pipeline molecules in various phases of drug development. READ MORE >

1.1 List of Tables
1.2 List of Figures

2 Global Diabetes Market: Introduction
2.1 Research Report Guidance

3 Global Diabetes Market: Market Overview
3.1 Introduction
3.2 Unmet Needs
3.2.1 Heart Risks Associated with some of the Oral Anti-diabetic Drugs
3.2.2 Carcinogenic Effects Associated With Insulin Analogs
3.2.3 Poor Patient Compliance
3.3 Revenue
3.4 Annual Cost of Therapy
3.5 Treatment Usage Patterns
3.5.1 Diseased Population
3.5.2 Treatment Seeking Population
3.5.3 Diagnosed Population
3.5.4 Prescription Population
3.6 Drivers and Restraints of Diabetes Market
3.6.1 Drivers of Diabetes Market
3.6.2 Restraints of Diabetes Market

4 Global Diabetes Market: Geographical Landscape
4.1 The US
4.1.1 Revenue
4.1.2 Annual Cost of Therapy
4.1.3 Treatment Usage Patterns
4.2 Top Five EU Countries
4.2.1 Revenue
4.2.2 Annual Cost of Therapy
4.2.3 Treatment Usage Patterns
4.3 Japan
4.3.1 Revenue
4.3.2 Annual Cost Therapy
4.3.3 Treatment Usage Patterns

5 Global Diabetes Market: Therapeutic Landscape
5.1 Type 1 Diabetes Market
5.1.1 Introduction
5.1.2 Symptoms
5.1.3 Treatment
5.1.4 Unmet need
5.1.5 Revenue
5.1.6 Annual Cost of therapy
5.1.7 Treatment Usage Patterns
5.1.8 Drivers and Restraints for the Type 1 Diabetes Market
5.2 Type 2 diabetes Therapeutics Market
5.2.1 Introduction
5.2.2 Symptoms
5.2.3 Treatment
5.2.4 Unmet need
5.2.5 Revenue
5.2.6 Annual Cost of therapy
5.2.7 Treatment Usage Patterns
5.2.8 Drivers and Restraints for the Type 2 Diabetes Market
5.3 Revenues by Class of Drugs of Type 2 Diabetes

6 Global Diabetes Market: Pipeline Analysis
6.1 Introduction
6.1.1 Research and Development Pipeline – Type 1 Diabetes
6.1.2 Research and Development Pipeline – Type 2 Diabetes
6.2 Innovations in Diabetes Treatment
6.2.1 Insulin in Pills (Oral Delivery)
6.2.2 Promising Treatments for Diabetic Retinopathy
6.2.3 Biomarkers in Diabetes
6.2.4 Combination Drugs are an Important Part of the Diabetes Therapeutics Pipeline
6.3 Drug Delivery in Diabetes
6.3.1 Factors Determining Preference for Drug Delivery
6.3.2 Desirable Drug Delivery Methods for Diabetes are Currently Unavailable
6.3.3 Innovation in Drug Delivery Systems
6.4 Profiles of Promising Drugs in the Diabetes Market
6.4.1 rhGAD65 (Diamyd)
6.4.2 DiaPep277
6.4.3 Otelixizumab
6.4.4 Oral-lyn
6.4.5 BMS-512148 (dapagliflozin)
6.4.6 Victoza (liraglutide)
6.4.7 D-Tagatose
6.4.8 JNJ-28431754 (canagliflozin)
6.4.9 MB07803

7 Global Diabetes Market: Competitive Landscape
7.1 Diabetes Market Overview
7.1.1 Human Insulin Products and Oral Anti-diabetic Drugs Like Actos Group (Actos and Actoplus met) and Lantus Have Led Market Growth
7.2 Market Share Analysis: Diabetes
7.3 Competitive Profiling
7.3.1 Novo Nordisk
7.3.2 Sanofi-Aventis
7.3.3 Takeda
7.3.4 Eli Lilly
7.3.5 GlaxoSmithKline (GSK)
7.3.6 Merck & Co Inc
7.3.7 Amylin Pharmaceuticals

8 Global Diabetes Market: M&A Landscape
8.1 Overview
8.1.1 M&A by Geography
8.1.2 M&A by Value ($)
8.2 R&D Licensing Agreements
8.2.1 Deals by Geography
8.2.2 Deals by Value ($)

9 Global Diabetes Market: Appendix
9.1 Market Definitions
9.2 Abbreviations
9.3 Research Methodology
9.3.1 Coverage
9.3.2 Secondary Research
9.3.3 Primary Research
9.3.4 Forecasts
9.3.5 Expert Panel Validation
9.4 Contact Us
9.5 Disclaimer
9.6 Sources

1.1 List of Tables
Table 1: Diabetes Therapeutics Market, Global, Revenue ($bn), 2001-2009
Table 2: Diabetes Therapeutics Market, Global, Revenue ($bn), 2009-2016
Table 3: Diabetes Therapeutics Market, Global, Annual Cost of Therapy ($), 2001-2009
Table 4: Diabetes Therapeutics Market, Global, Annual Cost of Therapy ($), 2009-2016
Table 5: Diabetes Therapeutics Market, Global, Treatment Usage Patterns (millions), 2001-2009
Table 6: Diabetes Therapeutics Market, Global, Treatment Usage Patterns(millions), 2009-2016
Table 7: Diabetes Market, Global, Revenue Analysis by Geography ($bn), 2001-2009
Table 8: Diabetes Market, Global, Revenue Analysis by Geography ($bn), 2009-2016
Table 9: Diabetes Market, The US, Revenues ($bn), 2001-2009
Table 10: Diabetes Therapeutics Market, The US, Revenues ($bn), 2009-2016
Table 11: Diabetes Therapeutics Market, The US, Annual Cost of Therapy ($), 2001-2009
Table 12: Diabetes Therapeutics Market, The US, Annual Cost of Therapy ($), 2009-2016
Table 13: Diabetes Therapeutics Market, The US, Treatment Usage Patterns (millions), 2001-2009
Table 14: Diabetes Therapeutics Market, The US, Treatment Usage Patterns (millions), 2009-2016
Table 15: Diabetes Therapeutics Market, Top Five Countries of Europe, Revenues ($bn), 2001-2009
Table 16: Diabetes Therapeutics Market, Top Five Countries of Europe, Revenues ($bn), 2009-2016
Table 17: Diabetes Therapeutics Market, Top Five Countries of Europe, Annual Cost of Therapy ($), 2001-2009
Table 18: Diabetes Therapeutics Market, Top Five Countries of Europe, Annual Cost of Therapy ($), 2009-2016
Table 19: Diabetes Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns (millions), 2001-2009
Table 20: Diabetes Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns (millions), 2009-2016
Table 21: Diabetes Therapeutics Market, Japan, Revenue ($bn), 2001-2009
Table 22: Diabetes Therapeutics Market, Japan, Revenue ($bn), 2009-2016
Table 23: Diabetes Therapeutics Market, Japan, Annual Cost of Therapy ($), 2001-2009
Table 24: Diabetes Therapeutics Market, Japan, Annual Cost of Therapy ($), 2009-2016
Table 25: Diabetes Therapeutics Market, Japan, Treatment Usage Patterns (millions), 2001-2009
Table 26: Diabetes Market, Japan, Treatment Usage Patterns(millions), 2009-2016
Table 27: Type 1 Diabetes Therapeutics Market, Types of Insulin Regimen
Table 28: Type 1 Diabetes Therapeutics Market, Global, Revenue ($bn), 2001-2009
Table 29: Type 1 Diabetes Therapeutics Market, Global, Revenue ($bn), 2009-2016
Table 30: Type 1 Diabetes Therapeutics Market, Global, Annual Cost of Therapy ($), 2001-2009
Table 31: Type 1 Diabetes Therapeutics Market, Global, Annual Cost of Therapy ($), 2009-2016
Table 32: Type 1 Diabetes Therapeutics Market, Global, Treatment Usage Patterns (millions), 2001-2009
Table 33: Type 1 Diabetes Therapeutics Market, Global, Treatment Usage Patterns (millions), 2009-2016
Table 34: Type 2 Diabetes Therapeutics Market, Global, Revenue ($bn), 2001-2009
Table 35: Type 2 Diabetes Therapeutics Market, Global, Revenue ($bn), 2009-2016
Table 36: Type 2 Diabetes Therapeutics Market, Global, Annual Cost of Therapy ($), 2001-2009
Table 37: Type 2 Diabetes Therapeutics Market, Global, Annual Cost of Therapy ($), 2009-2016
Table 38: Type 2 Diabetes Therapeutics Market, Global, Treatment Usage Patterns (millions), 2001-2009
Table 39: Type 2 Diabetes Therapeutics Market, Global, Treatment Usage Patterns (millions), 2009-2016
Table 40: Type 2 Diabetes Therapeutics Market, Global, Revenues By Class of Drugs ($bn), 2001-2009
Table 41: Type 2 Diabetes Therapeutics Market, Global, Revenues By Class of Drugs ($bn), 2009-2016
Table 42: Type 1 Diabetes Therapeutics Market, Global, R&D Pipeline by Phase, Phase III, 2010
Table 43: Type 1 Diabetes Therapeutics Market, Global, R&D Pipeline by Phase, Phase II, 2010
Table 44: Type 1 Diabetes Therapeutics Market, Global, R&D Pipeline by Phase, Phase I, 2010
Table 45: Type 1 Diabetes Therapeutics Market, Global, R&D Pipeline by Phase, Preclinical, 2010
Table 46: Type 2 Diabetes Therapeutics Market, Global, R&D Pipeline by Phase, Phase III, 2010
Table 47: Type 2 Diabetes Therapeutics Market, Global, R&D Pipeline by Phase, Phase II, 2010
Table 48: Diabetes Market, Global, R&D Pipeline by Phase in Type 2 Diabetes Market, Phase I, 2010
Table 49: Type 2 Diabetes Therapeutics Market, Global, R&D Pipeline by Phase, Preclinical, 2010
Table 50: Diabetes Therapeutics Markets, Factors Determining Preference of Drug Delivery in Diabetes, 2010
Table 51: Desirable Drug Delivery Methods for Diabetes are Currently Unavailable, 2010
Table 52: Diabetes Therapeutics Market, Novo Nordisk, Pipeline Products, 2010
Table 53: Diabetes Therapeutics Market, Sanofi-Aventis, Pipeline Products, 2010
Table 54: Diabetes Market, Takeda, Pipeline Products, 2010
Table 55: Diabetes Therapeutics Market, Eli Lilly, Pipeline Products, 2010
Table 56: Diabetes Therapeutics Market, GSK, Pipeline Products, 2010
Table 57: Diabetes Therapeutics Market, Merck, Pipeline Products, 2010
Table 58: Diabetes Therapeutics Market, Amylin, Pipeline Products, 2010

1.2 List of Figures
Figure 1: Diabetes Therapeutics Market, Global, Revenue($m), 2001-2016
Figure 2: Diabetes Therapeutics Market, Global, Annual Cost of Therapy ($), 2001-2016
Figure 3: Diabetes Therapeutics Market, Global, Treatment Usage Patterns (‘000), 2001-2016
Figure 4: Diabetes Therapeutics Market, Global, Diseased Population (‘000), 2001-2016
Figure 5: Diabetes Therapeutics Market, Global, Treatment Seeking Population (‘000), 2001-2016
Figure 6: Diabetes Therapeutics Market, Global, Diagnosis Population (‘000), 2001-2016
Figure 7: Diabetes Therapeutics Market, Global, Prescription Population (‘000), 2001-2016
Figure 8: Diabetes Market, Global, Revenue Analysis by Geography ($bn), 2001-2016
Figure 9: Diabetes Therapeutics Market, The US, Revenue ($m), 2001-2016
Figure 10: Diabetes Therapeutics Market, The US, Annual Cost of Therapy ($), 2001-2016
Figure 11: Diabetes Therapeutics Market, The US, Treatment Usage Patterns (‘000), 2001-2016
Figure 12: Diabetes Therapeutics Market, the US, Diseased Population (‘000), 2001-2016
Figure 13: Diabetes Therapeutics Market, the US, Treatment Seeking Population (‘000), 2001-2016
Figure 14: Diabetes Therapeutics Market, The US, Diagnosis Population (‘000), 2001-2016
Figure 15: Diabetes Therapeutics Market, The US, Prescription Population (‘000), 2001-2016
Figure 16: Diabetes Therapeutics Market, Top Five Countries of Europe, Revenue ($m), 2001-2016
Figure 17: Diabetes Therapeutics Market, Top Five Countries of Europe, Annual Cost of Therapy ($), 2001-2016
Figure 18: Diabetes Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns (‘000), 2001-2016
Figure 19: Diabetes Therapeutics Market, Top Five Countries of Europe, Diseased Population (‘000), 2001-2016
Figure 20: Diabetes Therapeutics Market, Top Five Countries of Europe, Treatment Seeking Population (‘000), 2001-2016
Figure 21: Diabetes Therapeutics Market, Top Five Countries of Europe, Diagnosis Population (‘000), 2001-2016
Figure 22: Diabetes Therapeutics Market, Top Five Countries of Europe, Prescription Population (‘000), 2001-2016
Figure 23: Diabetes Therapeutics Market, Japan, Revenue ($m), 2001-2016
Figure 24: Diabetes Therapeutics Market, Japan, Annual Cost of Therapy ($), 2001-2016
Figure 25: Diabetes Therapeutics Market, Japan, Treatment Usage Patterns (‘000), 2001-2016
Figure 26: Diabetes Therapeutics Market, Japan, Diseased Population (‘000), 2001-2016
Figure 27: Diabetes Therapeutics Market, Japan, Treatment Seeking Population (‘000), 2001-2016
Figure 28: Diabetes Therapeutics Market, Japan, Diagnosis Population (‘000), 2001-2016
Figure 29: Diabetes Therapeutics Market, Japan, Prescription Population (‘000), 2001-2016
Figure 30: Type 1 Diabetes Therapeutics Market, Global, Unmet Need, 2010
Figure 31: Type 1 Diabetes Therapeutics Market, Global, Revenue ($m), 2001-2016
Figure 32: Type 1 Diabetes Therapeutics Market, Global, Annual Cost of Therapy ($), 2001-2016
Figure 33: Type 1 Diabetes Therapeutics Market, Global, Treatment Usage Patterns (‘000), 2001-2016
Figure 34: Type 1 Diabetes Therapeutics Market, Global, Diseased Population (‘000), 2001-2016
Figure 35: Type 1 Diabetes Therapeutics Market, Global, Treatment Seeking Population (‘000), 2001-2016
Figure 36: Type 1 Diabetes Therapeutics Market, Global, Diagnosis Population (‘000), 2001-2016
Figure 37: Type 1 Diabetes Therapeutics Market, Global, Prescription Population (‘000), 2001-2016
Figure 38: Type 1 Diabetes Therapeutics Market, Global, Drivers and Restraints, 2009
Figure 39: Type 2 Diabetes Therapeutics Market, Global, Unmet Need, 2010
Figure 40: Type 2 Diabetes Therapeutics Market, Global, Revenues ($m), 2001-2016
Figure 41: Type 2 Diabetes Therapeutics Market, Global, Annual Cost of Therapy ($), 2001-2016
Figure 42: Type 2 Diabetes Therapeutics Market, Global, Treatment Usage Patterns (‘000), 2001-2016
Figure 43: Type 2 Diabetes Therapeutics Market, Global, Diseased Population (‘000), 2001-2016
Figure 44: Type 2 Diabetes Therapeutics Market, Global, Treatment Seeking Population (‘000), 2001-2016
Figure 45: Type 2 Diabetes Therapeutics Market, Global, Diagnosis Population (‘000), 2001-2016
Figure 46: Type 2 Diabetes Therapeutics Market, Global, Prescription Population (‘000), 2001-2016
Figure 47:Type 2 Diabetes Therapeutics Market , Global, Market Drivers and Barriers, 2009-2016
Figure 48: Type 2 Diabetes Therapeutics Market , Global, Market Share by Class of Drugs, 2009-2016
Figure 49: Type 2 Diabetes Therapeutics Market, Global, Revenues By Class of Drugs ($bn), 2001-2009
Figure 50: Type 2 Diabetes Therapeutics Market, Global, Revenues By Class of Drugs ($bn), 2009-2016
Figure 51: Diabetes Therapeutics Market, Global, R&D Pipeline by Indication (%), 2010
Figure 52: Diabetes Therapeutics Market, Global, R&D Pipeline by Phase (%), 2010
Figure 53: Type 1 Diabetes Therapeutics Market, Global, R&D Pipeline by Phase (%), 2010
Figure 54: Type 2 Diabetes Therapeutics Market, Global, R&D Pipeline by Phase (%), 2010
Figure 55: Diabetes Therapeutics Market, Global, Share of Top Manufacturers (%), 2010
Figure 56: Diabetes Therapeutics Market, Global, Revenue of Top Seven Players ($m), 2007-2009
Figure 57: Diabetes Therapeutics Market, Novo Nordisk, Revenue Segments (%), 2009
Figure 58: Diabetes Therapeutics Market, Novo Nordisk, Revenue by Product (%), 2009
Figure 59: Diabetes Therapeutics Market, Novo Nordisk, SWOT Analysis, 2010
Figure 60: Diabetes Therapeutics Market, Sanofi-Aventis, Revenue Segment (%), 2009
Figure 61: Diabetes Therapeutics Market, Sanofi-Aventis, Diabetes Revenue by Product (%), 2009
Figure 62: Diabetes Therapeutics Market, Sanofi-Aventis, SWOT Analysis, 2010
Figure 63: Diabetes Therapeutics Market, Takeda, Revenue Segments (%), 2009
Figure 64: Diabetes Therapeutics Market, SWOT Analysis, Takeda, 2010
Figure 65: Diabetes Therapeutics Market, Eli Lilly, Revenue Segments (%), 2009
Figure 66: Diabetes Therapeutics Market, Eli Lilly, Diabetes Revenue by Product (%), 2009
Figure 67: Diabetes Therapeutics Market, SWOT Analysis, Eli Lilly, 2010
Figure 68: Diabetes Therapeutics Market , GSK, Revenue Segments (%), 2009
Figure 69: Therapeutics Market, GSK, Diabetes Revenue by Product (%), 2009
Figure 70: Diabetes Therapeutics Market, GSK, SWOT Analysis, 2010
Figure 71: Diabetes Therapeutics Market, Merck, Diabetes Revenue as Percentage of Total Revenue (%), 2009
Figure 72: Diabetes Therapeutics Market, Merck, SWOT Analysis, 2010
Figure 73: Diabetes Therapeutics Market, Amylin, Diabetes Revenue as Percentage of Total Revenue (%), 2009
Figure 74: Diabetes Therapeutics Market, Amylin, Diabetes Revenue by Product (%), 2009
Figure 75: Diabetes Therapeutics Market, Amylin, SWOT Analysis, 2010
Figure 76: Diabetes Therapeutics Market, Global, Major M&As By Geography (%), n=48, 2009-2010
Figure 77: Diabetes Therapeutics Market, Global, Major M&As By Value ($), n=48, 2009-2010
Figure 78: Diabetes Therapeutics Market, Global, Major Licensing Agreements By Geography ($), n=76, 2009-2010
Figure 79: Diabetes Therapeutics Market, Global, Major Licensing Agreement By Value ($), n=76, 2009-2010
Figure 80: Research Market Forecasting Model

- Novo Nordisk
- Sanofi-Aventis
- Takeda
- Eli Lilly
- GlaxoSmithKline (GSK)
- Merck & Co Inc
- Amylin Pharmaceuticals

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos